BioSpace News Archive

Sojitz and Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced that they have entered into a binding definitive agreement.

SPR Therapeutics announced the publication of a multicenter double-blind randomized, placebo-controlled trial of individuals experiencing moderate-to-severe postoperative pain following knee replacement and treatment with the SPRINT PNS System.

Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, reported financial results for the first quarter of 2024 and provided a corporate update.

BioArctic AB’s partner Eisai announced that they have initiated the rolling submission of a Biologics License Application to the U.S. Food and Drug Administration for lecanemab-irmb subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA.

FibroBiologics, Inc. has filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, with the U.S. Securities and Exchange Commission.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced that entities affiliated with CRG Servicing LLC have converted Series A and Series B Convertible Preferred Stock to Common Stock.

Satellos Bioscience Inc. announced the results of its Annual and Special Meeting of Shareholders held today, May 14, 2024.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the quarter ended March 31, 2024.

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that it will host a webcast to discuss its Q1 2024 business highlights.